A phase 1/2 trial of IBB0979 in advanced solid tumours, run by SUNHO(China)BioPharmaceutical CO., Ltd., now recruiting.
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05991583 by SUNHO(China)BioPharmaceutical CO., Ltd., with 25 participants planned, started 2023-07-03 and due to reach its primary completion in 2025-11-30. Interventions recorded: IBB0979.
Shares SunHo Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SunHo Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SunHo Biopharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.